Transenterix Inc (NASDAQ:TRXC) shares were down NaN on Wednesday . The stock traded as low as $2.65 and last traded at $0.00. Approximately 9,340,125 shares changed hands during trading, an increase of Infinity from the average daily volume of 0 shares.
Several research analysts recently weighed in on TRXC shares. Ladenburg Thalmann Financial Services set a $5.00 price objective on shares of Transenterix and gave the stock a “buy” rating in a research note on Friday, October 20th. Zacks Investment Research lowered shares of Transenterix from a “buy” rating to a “sell” rating in a research note on Tuesday, August 8th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and issued a $4.00 price target (up previously from $3.75) on shares of Transenterix in a research note on Monday.
In other news, insider Todd Pope sold 600,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 18th. The shares were sold at an average price of $3.68, for a total transaction of $2,208,000.00. Following the completion of the sale, the insider now owns 462,644 shares of the company’s stock, valued at approximately $1,702,529.92. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.
Several hedge funds have recently made changes to their positions in the company. Royal Bank of Canada grew its position in shares of Transenterix by 17.1% during the 2nd quarter. Royal Bank of Canada now owns 418,867 shares of the company’s stock worth $298,000 after buying an additional 61,034 shares during the period. Global X Management Co. LLC grew its position in shares of Transenterix by 238.3% during the 2nd quarter. Global X Management Co. LLC now owns 331,075 shares of the company’s stock worth $235,000 after buying an additional 233,213 shares during the period. LMR Partners LLP acquired a new stake in shares of Transenterix during the 2nd quarter worth approximately $189,000. UBS Oconnor LLC acquired a new stake in shares of Transenterix during the 2nd quarter worth approximately $390,000. Finally, Goldman Sachs Group Inc. grew its position in shares of Transenterix by 7,137.7% during the 2nd quarter. Goldman Sachs Group Inc. now owns 1,203,199 shares of the company’s stock worth $854,000 after buying an additional 1,186,575 shares during the period.
Transenterix Company Profile
TransEnterix, Inc is a medical device company. The Company is focused on the development and commercialization of ALF-X Surgical Robotic System (the ALF-X System), and SurgiBot System. The Company’s ALF-X System is a multi-port robotic surgery system, which allows multiple robotic arms to control instruments and a camera.
Receive News & Ratings for Transenterix Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Transenterix Inc and related companies with MarketBeat.com's FREE daily email newsletter.